Artificial Cell Technologies
Artificial Cell Technologies (ACT) is a New Haven-based biotechnology company focused on redefining vaccine manufacturing through proprietary synthetic vaccine technology. Their innovative approach enables rapid, on-demand, and personalized vaccine production, significantly faster and more cost-effective than traditional methods. ACT's mission is to develop and deploy synthetic vaccines for infectious diseases, especially targeting the developing world, with a focus on decentralizing manufacturing and improving global health outcomes.
Industries
Nr. of Employees
small (1-50)
Artificial Cell Technologies
Patents
Products
Synthetic malaria vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting falciparum malaria, produced via multilayer polypeptide deposition onto particulate cores; reported progression toward Phase 1 clinical trial.
Synthetic RSV vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting respiratory syncytial virus (RSV) using multilayer polypeptide assembly onto particulate cores.
Portable Vaccine Manufacturing Device and Cleanroom System
A small, readily transportable, aseptic closed-loop, computer-controlled manufacturing device housed in a 50-foot portable, self-contained cleanroom.
Synthetic Microparticle Vaccines
Fully synthetic, temperature-stable, highly immunogenic microparticle vaccines produced by electrostatic layer-by-layer deposition of poly amino acids onto a calcium carbonate core.
Respiratory Syncytial Virus (RSV) Vaccine
A synthetic RSV vaccine candidate utilizing proprietary layer-by-layer (LbL) polypeptide nanofilm technology, currently in pre-clinical development.
Malaria Vaccine
A synthetic malaria vaccine candidate utilizing proprietary layer-by-layer (LbL) polypeptide nanofilm technology, currently in pre-clinical development with preparation for phase 1 human clinical trials.
Synthetic malaria vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting falciparum malaria, produced via multilayer polypeptide deposition onto particulate cores; reported progression toward Phase 1 clinical trial.
Synthetic RSV vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting respiratory syncytial virus (RSV) using multilayer polypeptide assembly onto particulate cores.
Portable Vaccine Manufacturing Device and Cleanroom System
A small, readily transportable, aseptic closed-loop, computer-controlled manufacturing device housed in a 50-foot portable, self-contained cleanroom.
Synthetic Microparticle Vaccines
Fully synthetic, temperature-stable, highly immunogenic microparticle vaccines produced by electrostatic layer-by-layer deposition of poly amino acids onto a calcium carbonate core.
Respiratory Syncytial Virus (RSV) Vaccine
A synthetic RSV vaccine candidate utilizing proprietary layer-by-layer (LbL) polypeptide nanofilm technology, currently in pre-clinical development.
Malaria Vaccine
A synthetic malaria vaccine candidate utilizing proprietary layer-by-layer (LbL) polypeptide nanofilm technology, currently in pre-clinical development with preparation for phase 1 human clinical trials.
Services
Mobile manufacturing service concept using compact aseptic cleanrooms and computer-controlled devices to produce synthetic vaccines near target populations.
Mobile manufacturing service concept using compact aseptic cleanrooms and computer-controlled devices to produce synthetic vaccines near target populations.
Expertise Areas
- Synthetic vaccine manufacturing
- Layer-by-layer nanoparticle assembly
- Decentralized/mobile vaccine production
- Temperature-stable vaccine formulation
Key Technologies
- Electrostatic layer-by-layer deposition
- Polypeptide nanofilm multilayers
- Microparticle vaccine platforms
- Inorganic particulate cores (calcium carbonate) for particle scaffolds